Rapport Therapeutics
RAPP
70 hedge funds and large institutions have $649M invested in Rapport Therapeutics in 2024 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 5 closing their positions.
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
36% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 14
27% more funds holding
Funds holding: 55 → 70 (+15)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
22.23% more ownership
Funds ownership: 77.76% → 99.99% (+22%)
12% more capital invested
Capital invested by funds: $582M → $649M (+$67M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4M |
| 2 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$2.56M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.43M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.13M |
| 5 |
Jennison Associates
New York
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$9.68M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.26M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$2M |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
-$613K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$494K |
RAPP Hedge Fund Activity: Q4 2024 in Review
70 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Rapport Therapeutics (RAPP) for Q4 2024, worth a combined $649M — up 12% from $582M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new RAPP positions and 5 closed out — a net gain of 15 holders — while 19 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $4M. The largest seller was Perceptive Advisors, cutting an estimated $9.68M.
- 70 institutional investors held Rapport Therapeutics (RAPP) as of Q4 2024, up from 55 in Q3 2024.
- Funds reported $649M of Rapport Therapeutics stock for Q4 2024, up 12% quarter-over-quarter.
- 20 funds opened new Rapport Therapeutics positions in Q4 2024 and 5 closed out, a net change of +15 holders.
- The largest Rapport Therapeutics buyer in Q4 2024 was BlackRock, an estimated $4M added.
- The largest Rapport Therapeutics seller in Q4 2024 was Perceptive Advisors, an estimated $9.68M sold.
Based on aggregated 13F filings for Q4 2024.